2013
|
Sign up to set email alerts
Phytoestrogens for menopausal vasomotor symptoms
Search citation statements
Order By: Relevance
Paper Sections
Select...
279
27
24
3
Citation Types
6
153
0
33
Year Published
Range
2000
20002026
2026Publication Types
Select...
235
76
11
Relationship
0
322
Authors
Journals
Cited by 318 publications
(192 citation statements)
References 180 publications
6
153
0
33
Order By: Relevance
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…The placebo effect of 58% noted in the current study is in agreement with that observed in the literature, and when a menopause-specific QoL questionnaire was used in a demographically similar population (28). The placebo effect in menopause studies may range from 1 to 59% with phytoestrogens (29), which is similar to the placebo effect noted with HRT for vasomotor symptoms (30) and a clinically significant 33% placebo effect has been observed with pharmaceutical products (31). To mitigate the placebo effect on menopausal symptoms especially on hot flush a sub-group analysis based on hot flush severity (at screening) was done.…”
Section: Discussion
supporting
confidence: 91%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…The placebo effect of 58% noted in the current study is in agreement with that observed in the literature, and when a menopause-specific QoL questionnaire was used in a demographically similar population (28). The placebo effect in menopause studies may range from 1 to 59% with phytoestrogens (29), which is similar to the placebo effect noted with HRT for vasomotor symptoms (30) and a clinically significant 33% placebo effect has been observed with pharmaceutical products (31). To mitigate the placebo effect on menopausal symptoms especially on hot flush a sub-group analysis based on hot flush severity (at screening) was done.…”
Section: Discussion
supporting
confidence: 91%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In this regard, some studies found a benefit compared with placebo [ 11 12 13 14 16 42 43 44 45 46 ], and others did not [ 47 48 49 ].The wide range in the amount of total isoflavones and the other active compounds, dose-schedule, time of follow-up and the severity of symptoms in these studies may explain these differences. Notably, in our study the reduction observed in overall and moderate-to-severe HFs seemed to surpass the estimated placebo effect described in other studies [ 38 ], similar to what has been described in the study of Nahas et al [ 13 ]. In this study, Nahas et al [ 13 ] found that isoflavones were significantly superior to placebo in reducing the frequency and severity of HFs ( P < 0.001) in postmenopausal women with a symptom profile similar to that reported in our study and a 10-month follow-up period.…”
Section: Discussion
supporting
confidence: 90%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In contrast, we found that the frequency of lignan intake was significantly associated with increased odds of hot flashes and decreased odds of vaginal dryness. The lack of a relationship between symptoms and the coumestrol consumption range is consistent with the lack of findings in supplementation studies [32]. In the meta-analysis of clinical trials mentioned above, the use of phytoestrogens was not associated with a change in the number of night sweats [36].…”
Section: Discussion
supporting
confidence: 69%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…The placebo effect of 58% noted in the current study is in agreement with that observed in the literature, and when a menopause-specific QoL questionnaire was used in a demographically similar population (28). The placebo effect in menopause studies may range from 1 to 59% with phytoestrogens (29), which is similar to the placebo effect noted with HRT for vasomotor symptoms (30) and a clinically significant 33% placebo effect has been observed with pharmaceutical products (31). To mitigate the placebo effect on menopausal symptoms especially on hot flush a sub-group analysis based on hot flush severity (at screening) was done.…”
Section: Discussion
supporting
confidence: 91%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In this regard, some studies found a benefit compared with placebo [ 11 12 13 14 16 42 43 44 45 46 ], and others did not [ 47 48 49 ].The wide range in the amount of total isoflavones and the other active compounds, dose-schedule, time of follow-up and the severity of symptoms in these studies may explain these differences. Notably, in our study the reduction observed in overall and moderate-to-severe HFs seemed to surpass the estimated placebo effect described in other studies [ 38 ], similar to what has been described in the study of Nahas et al [ 13 ]. In this study, Nahas et al [ 13 ] found that isoflavones were significantly superior to placebo in reducing the frequency and severity of HFs ( P < 0.001) in postmenopausal women with a symptom profile similar to that reported in our study and a 10-month follow-up period.…”
Section: Discussion
supporting
confidence: 90%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In contrast, we found that the frequency of lignan intake was significantly associated with increased odds of hot flashes and decreased odds of vaginal dryness. The lack of a relationship between symptoms and the coumestrol consumption range is consistent with the lack of findings in supplementation studies [32]. In the meta-analysis of clinical trials mentioned above, the use of phytoestrogens was not associated with a change in the number of night sweats [36].…”
Section: Discussion
supporting
confidence: 69%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…The placebo effect of 58% noted in the current study is in agreement with that observed in the literature, and when a menopause-specific QoL questionnaire was used in a demographically similar population (28). The placebo effect in menopause studies may range from 1 to 59% with phytoestrogens (29), which is similar to the placebo effect noted with HRT for vasomotor symptoms (30) and a clinically significant 33% placebo effect has been observed with pharmaceutical products (31). To mitigate the placebo effect on menopausal symptoms especially on hot flush a sub-group analysis based on hot flush severity (at screening) was done.…”
Section: Discussion
supporting
confidence: 91%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In this regard, some studies found a benefit compared with placebo [ 11 12 13 14 16 42 43 44 45 46 ], and others did not [ 47 48 49 ].The wide range in the amount of total isoflavones and the other active compounds, dose-schedule, time of follow-up and the severity of symptoms in these studies may explain these differences. Notably, in our study the reduction observed in overall and moderate-to-severe HFs seemed to surpass the estimated placebo effect described in other studies [ 38 ], similar to what has been described in the study of Nahas et al [ 13 ]. In this study, Nahas et al [ 13 ] found that isoflavones were significantly superior to placebo in reducing the frequency and severity of HFs ( P < 0.001) in postmenopausal women with a symptom profile similar to that reported in our study and a 10-month follow-up period.…”
Section: Discussion
supporting
confidence: 90%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In contrast, we found that the frequency of lignan intake was significantly associated with increased odds of hot flashes and decreased odds of vaginal dryness. The lack of a relationship between symptoms and the coumestrol consumption range is consistent with the lack of findings in supplementation studies [32]. In the meta-analysis of clinical trials mentioned above, the use of phytoestrogens was not associated with a change in the number of night sweats [36].…”
Section: Discussion
supporting
confidence: 69%